Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VNX001 in Interstitial Cystitis/Bladder Pain Syndrome
NCT06394830Phase 2Recruiting
- Sponsor
- Urigen Pharmaceuticals, Inc.
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VNX001 in interstitial cystitis (IC), bladder pain syndrome (BPS), sponsored by Urigen Pharmaceuticals, Inc.. Started Dec 2024; status: recruiting.
02
Drugs
VNX001
03
Conditions
interstitial cystitis (IC)bladder pain syndrome (BPS)
Beyond the preview
Go deeper on NCT06394830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394830.